Partner: Beata Franczyk

Medical University of Lodz (PL)

Recent publications
1.Franczyk B., Gluba-Brzózka A., Olszewski R., Parolczyk M., Rysz-Górzyńska M., Rysz J., miRNA biomarkers in renal disease, International Urology and Nephrology, ISSN: 0301-1623, DOI: 10.1007/s11255-021-02922-7, Vol.54, pp.575-588, 2022
Abstract:

Chronic kidney disease (CKD), which is characterized by the gradual loss of kidney function, is a growing worldwide problem due to CKD-related morbidity and mortality. There are no reliable and early biomarkers enabling the monitoring, the stratification of CKD progression and the estimation of the risk of CKD-related complications, and therefore, the search for such molecules is still going on. Numerous studies have provided evidence that miRNAs are potentially important par- ticles in the CKD field. Studies indicate that some miRNA levels can be increased in patients with CKD stages III–V and hemodialysis and decreased in renal transplant recipients (miR-143, miR-145 and miR-223) as well as elevated in patients with CKD stages III–V, decreased in hemodialysis patients and even more markedly decreased in renal transplant recipients (miR-126 and miR-155). miRNA have great potential of being sensitive and specific biomarkers in kidney diseases as they are tissue specific and stable in various biological materials. Some promising non-invasive miRNA biomarkers have already been recognized in renal disease with the potential to enhance diagnostic accuracy, predict prognosis and monitor the course of disease. However, large-scale clinical trials enrolling heterogeneous patients are required to evaluate the clinical value of miRNAs.

Keywords:

Chronic kidney disease

Affiliations:
Franczyk B.-Medical University of Lodz (PL)
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
Olszewski R.-IPPT PAN
Parolczyk M.-other affiliation
Rysz-Górzyńska M.-other affiliation
Rysz J.-Medical University of Lodz (PL)
2.Rysz J., Franczyk B., Ławiński J., Olszewski R., Ciałkowska-Rysz A., Gluba-Brzózka A., The impact of CKD on uremic toxins and gut microbiota, TOXINS, ISSN: 2072-6651, DOI: 10.3390/toxins13040252, Vol.13, No.4, pp.252-1-23, 2021
Abstract:

Numerous studies have indicated that the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) is strictly associated with the accumulation of toxic metabolites in blood and other metabolic compartments. This accumulation was suggested to be related to enhanced generation of toxins from the dysbiotic microbiome accompanied by their reduced elimination by impaired kidneys. Intestinal microbiota play a key role in the accumulation of uremic toxins due to the fact that numerous uremic solutes are generated in the process of protein fermentation by colonic microbiota. Some disease states, including CKD, are associated with the presence of dysbiosis, which can be defined as an “imbalanced intestinal microbial community with quantitative and qualitative changes in the composition and metabolic activities of the gut microbiota”. The results of studies have confirmed the altered composition and functions of gut microbial community in chronic kidney disease. In the course of CKD protein-bound uremic toxins, including indoxyl sulfate, p-cresyl glucuronide, p-cresyl sulfate and indole-3-acetic acid are progressively accumulated. The presence of chronic kidney disease may be accompanied by the development of intestinal inflammation and epithelial barrier impairment leading to hastened systemic translocation of bacterial-derived uremic toxins and consequent oxidative stress injury to the kidney, cardiovascular and endocrine systems. These findings offer new therapeutic possibilities for the management of uremia, inflammation and kidney disease progression and the prevention of adverse outcomes in CKD patients. It seems that dietary interventions comprising prebiotics, probiotics, and synbiotics could pose a promising strategy in the management of uremic toxins in CKD.

Keywords:

chronic kidney disease, uremic toxins, gut microbiota, cardiovascular risk

Affiliations:
Rysz J.-Medical University of Lodz (PL)
Franczyk B.-Medical University of Lodz (PL)
Ławiński J.-other affiliation
Olszewski R.-IPPT PAN
Ciałkowska-Rysz A.-Medical University of Lodz (PL)
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
3.Gluba-Brzózka A., Franczyk B., Olszewski R., Rysz J., The influence of inflammation on anemia in CKD patients, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms21030725, Vol.21, No.3, pp.725-1-25, 2020
Abstract:

Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient's life. It also enhances morbidity and mortality and hastens the KD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA. The discovery of new therapeutic approaches towards the treatment of anemia in CKD patients has become highly awaited. The treatment of anemia with erythropoietin (EPO) was associated with great benefits for some patients but not all.

Keywords:

inflammation, chronic kidney disease, anemia, anemia of inflammation, ESA hyporesponsiveness

Affiliations:
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
Franczyk B.-Medical University of Lodz (PL)
Olszewski R.-IPPT PAN
Rysz J.-Medical University of Lodz (PL)
4.Rysz J., Franczyk B., Ławiński J., Olszewski R., Gluba-Brzózka A., The role of metabolic factors in renal cancers, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms21197246, Vol.21, No.19, pp.7246-1-20, 2020
Abstract:

Anincreasing number of evidence indicates that metabolic factorsmayplay an important role in the evelopment and progression of certain types of cancers, including renal cell carcinoma (RCC). This tumour is the most common kidney cancer which accounts for approximately 3–5% of malignant tumours in adults. Numerous studies indicated that concomitant diseases, including diabetes mellitus (DM) and hypertension, as well as obesity, insulin resistance, and lipid disorders, may also influence the prognosis and cancer-specific overall survival. However, the results of studies concerning the impact of metabolic factors on RCC are controversial. It appears that obesity increases the risk of RCC development; however, it may be a favourable factor in terms of prognosis. Obesity is closely related to insulin resistance and the development of diabetes mellitus type 2 (DM2T) since the adipocytes in visceral tissue secrete substances responsible for insulin resistance, e.g., free fatty acids. Interactions between insulin and insulin-like growth factor (IGF) system appear to be of key importance in the development and progression of RCC; however, the exact role of insulin and IGFs in RCC pathophysiology remains elusive. Studies indicated that diabetes increased the risk of RCC, but it might not alter cancer-related survival. The risk associated with a lipid profile is most mysterious, as numerous studies provided conflicting results. Even though large studies unravelling pathomechanisms involved in cancer growth are required to finally establish the impact of metabolic factors on the development, progression, and prognosis of renal cancers, it seems that the monitoring of health conditions, such as diabetes, low body mass index (BMI), and lipid disorders is of high importance in clear-cell RCC.

Keywords:

renal cell carcinoma, obesity, insulin resistance, diabetes mellitus, lipid disorders

Affiliations:
Rysz J.-Medical University of Lodz (PL)
Franczyk B.-Medical University of Lodz (PL)
Ławiński J.-other affiliation
Olszewski R.-IPPT PAN
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
5.Gluba-Brzózka A., Franczyk B., Ciałkowska-Rysz A., Olszewski R., Rysz J., Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients, Nutrients, ISSN: 2072-6643, DOI: 10.3390/nu10060709, Vol.10, No.709, pp.1-12, 2018
Abstract:

In patients suffering from chronic kidney disease (CKD), the prevalence of cardiovascular disease is much more common than in the general population. The role of vitamin D deficiency had been underestimated until a significant association was found between vitamin D therapy and survival benefit in haemodialysis patients. Vitamin D deficiency is present even in the early stages of chronic kidney disease. The results of experimental studies have revealed the relationship between vitamin D deficiency and impairment of cardiac contractile function, higher cardiac mass and increased myocardial collagen content. Experimental models propose that intermediate end points for the relationship between vitamin D deficiency and higher risk of cardiovascular disease comprise diminished left ventricular hypertrophy (LVH), enhanced left ventricular diastolic function, anddecreasedfrequencyofheartfailure. Multipleobservationalstudieshavedemonstrated an association between the use of active vitamin D therapy in patients on dialysis and with CKD and improved survival. However, there are also many studies indicating important adverse effects of such treatment. Therefore, large randomized trials are required to analyze whether supplementation of vitamin D may affect outcomes and whether it is safe to be used in CKD patient

Keywords:

vitamin D, chronic kidney disease, cardiovascular disease, mortality, vitamin D analogues, treatment

Affiliations:
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
Franczyk B.-Medical University of Lodz (PL)
Ciałkowska-Rysz A.-Medical University of Lodz (PL)
Olszewski R.-IPPT PAN
Rysz J.-Medical University of Lodz (PL)
6.Gluba-Brzózka A., Franczyk B., Olszewski R., Banach M., Rysz J., Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases, International Journal of Molecular Sciences, ISSN: 1422-0067, DOI: 10.3390/ijms18061248, Vol.18, pp.1248-1-20, 2017
Abstract:

The prevalence of renal diseases is rising and reaching 5–15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are influenced not only by environmental but also by genetic factors. In some cases the disease is caused by mutation in a single gene and at that time severity depends on the presence of one or two utated alleles. In other cases, renal disease is associated with the presence of alteration within a gene or genes, but environmental factors are also necessary for the development of disease. Therefore, it seems that the analysis of genetic aspects should be a natural component of clinical and xperimental studies. The goal of personalized medicine is to determine the right drug,for the right patient,at the right time. Whole-genome examinations may help to change the approach to the disease and the patient resulting in the creation of“personalized medicine”with new diagnostic and treatment strategies designed on the basis of genetic background of each individual. The identification of high-risk patients in pharmacogenomics analyses will help to avoid many unwarranted side effects while optimizing treatment efficacy for individual patients. Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome. This review will focus on several areas of interest: renal disease pathogenesis, diagnosis, treatment, rate of progression and the prediction ofprognosis.

Keywords:

renal diseases, personalized medicine, treatment, diagnosis, biomarkers

Affiliations:
Gluba-Brzózka A.-WAM Teaching Hospital (PL)
Franczyk B.-Medical University of Lodz (PL)
Olszewski R.-IPPT PAN
Banach M.-Medical University of Lodz (PL)
Rysz J.-Medical University of Lodz (PL)